Table 1.
Patients’ baseline and clinical characteristics
| Group 1 N = 58 | Group 2 N = 219 | P | Group 1 N = 58 | Group 2A N = 156 | Group 2B N = 63 | P | |
|---|---|---|---|---|---|---|---|
| Age, years (mean ± SD) | 63 ± 8 | 64 ± 10 | 0.5 | 63 ± 8 | 63 ± 10 | 65 ± 10 | 0.6 |
| Men, N (%) | 37(63.8%) | 126(57.5%) | 0.4 | 37(63.8%) | 98(62.8%) | 28(44.4%) | 0.03 |
| Prior myocardial infarction, N (%) | 11(19.0%) | 64(29.3%) | 0.1 | 11(19.0%) | 42(27.1%) | 22(34.9%) | 0.1 |
| Smoking, N (%) | 12(20.7%) | 26(11.9%) | 0.04 | 12(20.7%) | 20(12.8%) | 6(9.5%) | 0.04 |
| Time from symptom onset, hours [median (interquartile range)] | 5.0(3.0–6.0) | 4.0(3.0–7.0) | 0.8 | 5.0(3.0–6.0) | 4.0(3.0–7.0) | 4.0(3.0–8.0) | 0.6 |
| Cardiogenic shock, N (%) | 8(13.8%) | 34(15.5%) | 0.7 | 8(13.8%) | 25(16.0%) | 9(14.3%) | 0.9 |
| Insulina, N (%) | 24(41.4%) | 138(63.8%) | 0.002 | 24(41.4%) | 91(58.3%) | 47(74.6%) | <0.001 |
| Metformina, N (%) | 34(58.6%) | 88(40.2%) | 0.02 | 34(58.6%) | 65(41.7%) | 23(36.5%) | 0.04 |
| Sulfonylureasa, N (%) | 19(32.8%) | 70(32.0%) | 0.8 | 19(32.8%) | 47(30.1%) | 23(36.5%) | 0.5 |
| HbA1c, (%) | 7.7(6.9–8.5) | 7.5(6.9–8.0) | 0.3 | 7.7(6.9–8.5) | 7.6(7.0–8.3) | 7.5(6.8–8.4) | 0.3 |
| LVEF, (%) [median (interquartile range)] | 47(45–51) | 40(35–45) | <0.001 | 47(45–51) | 42(35–45) | 39(32–42) | <0.001 |
| Hospital stay, days [median (interquartile range)] | 7.5(6–10) | 9(6–12) | 0.04 | 7.5(6–10) | 9(6–12) | 10(6–13) | 0.055 |
SD standard deviation; LVEF left ventricular ejection fraction
aSome patients were on more than one hypoglycemic agent